ReviewStem cell reviews and reports2013
Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.
Review in Stem cell reviews and reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Increased Myocardial Retention of Mesenchymal Stem Cells Post-MI by Pre-Conditioning Exercise Training.Stem cell reviews and reports · 2020Article
- Extracellular vesicles from bone marrow-derived mesenchymal stromal cells supportJournal of extracellular vesicles · 2018Article
- Remodeling an infarcted heart: novel hybrid treatment with transmyocardial revascularization and stem cell therapy.SpringerPlus · 2016Review
- ASC spheroid geometry and culture oxygenation differentially impact induction of preangiogenic behaviors in endothelial cells.Cell transplantation · 2015Article
- An update on stem cell therapies for acute coronary syndrome.Current cardiology reports · 2014Review
- Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo.Stem cell reports · 2014Article
- Proangiogenic compositions of microvesicles derived from human umbilical cord mesenchymal stem cells.PloS one · 2014Article
- Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine.Experimental & molecular medicine · 2013Review
- Adult stem cells and cardiac regeneration.Stem cell reviews and reports · 2013Article
- Noninvasive monitoring of oxidative stress in transplanted mesenchymal stromal cells.JACC. Cardiovascular imaging · 2013Article
- Human embryonic stem cell derived mesenchymal progenitors express cardiac markers but do not form contractile cardiomyocytes.PloS one · 2013Article
- Trophic actions of bone marrow-derived mesenchymal stromal cells for muscle repair/regeneration.Cells · 2012Article
- Functional multipotency of stem cells: what do we need from them in the heart?Stem cells international · 2012Article
- Cellular Therapy for Heart Failure.Current cardiology reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite current treatment options, cardiac failure is associated with significant morbidity and mortality highlighting a compelling clinical need for novel therapeutic approaches. Based on promising pre-clinical data, stem cell therapy has been suggested as a possible therapeutic strategy. Of the candidate cell types evaluated, mesenchymal stromal/stem cells (MSCs) have been widely evaluated due to their ease of isolation and ex vivo expansion, potential allogeneic utility and capacity to promote neo-angiogenesis and endogenous cardiac repair. However, the clinical application of MSCs for mainstream cardiovascular use is currently hindered by several important limitations, including suboptimal retention and engraftment and restricted capacity for bona fide cardiomyocyte regeneration. Consequently, this has prompted intense efforts to advance the therapeutic properties of MSCs for cardiovascular disease. In this review, we consider the scope of benefit from traditional plastic adherence-isolated MSCs and the lessons learned from their conventional use in preclinical and clinical studies. Focus is then given to the evolving strategies aimed at optimizing MSC therapy, including discussion of cell-targeted techniques that encompass the preparation, pre-conditioning and manipulation of these cells ex vivo, methods to improve their delivery to the heart and innovative substrate-directed strategies to support their interaction with the host myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.